3.4.22.46	(2S,3R,4R)-2-{[2-(2,3-dihydroxyphenyl)-5,8-dihydroxy-4-oxo-4H-chromen-7-yl]oxy}-4-hydroxy-4-(hydroxymethyl)tetrahydrofuran-3-yl alpha-D-galactopyranoside	-	201888	
3.4.22.46	2-(3,4-dihydroxyphenyl)ethyl 4-O-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-6-O-alpha-L-lyxopyranosyl-beta-D-glucopyranoside	-	201887	
3.4.22.46	CA074	epoxide-based inhibitor of cysteine proteinases, two-step overall irreversible inhibition, with step one being reversible and step two irreversible	4358	
3.4.22.46	CA074	-	4358	
3.4.22.46	E64	epoxide-based inhibitor of cysteine proteinases, two-step overall irreversible inhibition, with step one being reversible and step two irreversible. Extending E64 by addition of the dipeptide R-P to a compound termed E64-R-P-NH2, which irreversibly inhibits Lbpro with a Ki of 30 nM and k4 of 0.01/min, can serve as the basis for design of specific inhibitors of FMDV replication	1457	
3.4.22.46	E64-R-P-NH2	extending E64 by addition of the dipeptide R-P to a compound termed E64-R-P-NH2, which irreversibly inhibits Lbpro with a Ki of 30 nM and k4 of 0.01/min, can serve as the basis for design of specific inhibitors of FMDV replication	86537	
3.4.22.46	E64-R-P-NH2	-	86537	
3.4.22.46	additional information	sensitive to high ionic strength, 50% inactivation by 20 mM NaCl or 10 mM CaCl2	2	
3.4.22.46	additional information	self-processing inactivates leader proteinase nsp1alpha	2	
3.4.22.46	trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane	i.e. E-64	1306	
3.4.22.46	trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane	-	1306